The continuous glucose monitoring (CGM) developer Dexcom has officially opened its new €300 million ($325 million) state-of-the-art manufacturing and office facility in Athenry, Co. Galway. Constructed over a 25-month period by John Paul Construction and completed in early 2026, the 30,000-square-meter plant represents Dexcom’s first manufacturing site outside the United States. The complex features a highly technical production environment. It includes 4,200 square meters of ISO-certified cleanrooms, laboratories, and engineering spaces and a newly commissioned, energy-efficient wastewater treatment plant designed by the Coffey Group. The project was recently honored at the Engineering Excellence Awards 2026, winning Large Civil Project of the Year for its successful on-schedule delivery.
Representing one of the largest single private-sector investments in the West of Ireland, the highly automated plant is expected to create more than 1,000 skilled jobs for graduates and technicians, alongside the 500 roles generated during its construction phase. The facility is heavily focused on sustainability and green technologies, incorporating rooftop solar panels, 100 electric vehicle charging spaces, and a local nature trail. At full capacity, the Athenry site will produce up to 60 million CGM units annually, primarily focusing on the latest-generation Dexcom G7 wearable sensors to meet the rapidly expanding demand across European and international markets.
Ireland has favourable policies that promote foreign investment. Other companies such as Intel have also set up massive investments in the country. Dexcom’s new €300 million facility in Athenry and Intel’s massive €5 billion expansion at its Leixlip campus powerfully reinforce Ireland’s position as a premier global hub for advanced manufacturing. Together, these investments secure a highly resilient future for the country’s economy by diversifying high-tech output across two critical sectors, propelling the West of Ireland into a major MedTech export powerhouse with over 1,000 skilled jobs at Dexcom, while cementing Kildare’s role at the forefront of European semiconductor and AI silicon production with Intel. By generating thousands of specialized construction and engineering roles, advancing local research and development, and driving regional infrastructure development, these dual efforts heavily boost Ireland’s economic growth, technical talent pool, and geopolitical relevance in the global supply chains of healthcare and artificial intelligence.
May 10, 2023
Plans have been revealed for the construction of a new Dexcom manufacturing facility in Ireland. The facility will be developed by Dexcom, a US-based manufacturer of medical devices, at a cost of €300 million over the course of the following five years.
The California-headquartered company makes continuous glucose monitoring systems for people with diabetes. It confirmed that it would apply for authorization to plan for its first European facility at an IDA Ireland-owned land bank in Athenry. According to a statement from the inward investment agency, the plant will be able to create “millions” of Dexcom’s sensor devices annually.
When the site is fully operational, Dexcom anticipates producing up to 1,000 high-tech graduate and technician-level jobs in the area and 500 construction positions.
According to Barry Regan, executive vice-president of worldwide operations for Dexcom, “Ireland has an exceptional talent pool and an established medtech sector. This makes Athenry the perfect location to establish a new, cutting-edge manufacturing facility.”
Read Also: Wärtsilä and EDF Renewables UK to develop an energy storage system in Bramford
Dexcom’s new manufacturing facility in Ireland
It is a worldwide player’s second significant announcement in the past year in this particular field of medical devices. Last August, Abbott Laboratories said it would invest €440 million in Ireland, with plans for a sizable new production facility in Kilkenny and more jobs in Donegal. The company’s growth will create 1,000 new jobs for Irish citizens and establish the State as a global leader in manufacturing cutting-edge diabetic glucose monitoring devices.
The Dexcom G7 wearable device sends automatic glucose readings to a user’s smart device and has Ireland as one of its initial launch markets in October 2022. With the Dexcom G7’s increasing popularity in Europe, Mr. Regan stated: “We are pursuing an ambitious growth strategy that calls for increased manufacturing capacity to support our rapidly growing European user base.”
Following the product launch in the US market, the firm recently reported a revenue increase of 18% in the first quarter of 2023 compared to the same period last year, with total sales of more than $741.5 million. Dexcom anticipates revenues to increase to at least $3.4 billion in 2023, up 17% from 2022, and an adjusted profit margin of 26%.
Project Factsheet
Project Name: Dexcom Factory 4 (F4) & Health Tech Campus
Developer/Owner: Dexcom, Inc. (San Diego, US)
Location: IDA Ireland Strategic Landbank, Athenry, Co. Galway, Ireland
Project Type: Advanced MedTech manufacturing facility and corporate offices
Status: Completed & Officially Opened (Early 2026)
Construction Timeline: 25 months (Groundbreaking: January 2024)
Total Capital Investment: €300 million ($325 million USD) over 5 years
Economic Scale: One of the largest single private-sector investments in the West of Ireland
Job Creation (Construction Phase): 500 temporary construction roles
Local Contribution: Over €1 million paid to Galway County Council for regional public infrastructure
Technical Specifications & Facility Layout
- Campus Footprint: 80-acre site
- Total Building Area: 40,000 square meters (180,000 sq. ft.) across a four-story complex
- Core Infrastructure: Highly automated production lines, specialized laboratories, and engineering blocks
- Controlled Environments: High-specification ISO-certified cleanrooms utilizing energy-saver HVAC systems for precision airflow regulation
- Production Focus: High-volume commercial manufacture of real-time continuous glucose monitoring (CGM) systems, primarily the Dexcom G7 wearable sensor
Target Markets: European and international export supply chains
Sustainability and Environmental Engineering
- Green Certification: Submitted for LEED Gold certification
- Renewable Energy: Integrated rooftop solar photovoltaic (PV) array
- Transportation Management: 100 dedicated electric vehicle (EV) charging spaces, an on-site bike-sharing scheme, and a dedicated employee shuttle bus service connecting to Athenry Train Station and Galway City
- Biodiversity and Community: Development of a local nature trail and the planting of 600 native Irish Oak trees on-site
- Earthworks Efficiency: 170,000 cubic meters of topsoil and subsoil excavated and completely retained on-site during construction to minimize transport emissions
Project Team
Client / Developer: Dexcom International Ltd.
Support Agency: IDA Ireland (Irish Government Industrial Development Agency)
Main Building Contractor: John Paul Construction
Civil and Environmental Design: Coffey Group (Wastewater treatment facility)
HVAC Systems Design: MEA (Consulting Engineers) & Keane Environmental (Diffusion Energy Saver Fan Coil Units)
Architects: RKD Architects
Civil, Transportation, and Flood Risk Engineers: Clifton Scannell Emerson Associates (CSEA) (Project honored at the ACEI Engineering Excellence Awards 2026)
Project and Cost Management (Quantity Surveying): Linesight
Planning and Environmental Consultants: MKO (McCarthy Keville O’Sullivan)
Landscape Architects and Environmental Consultants: Brady Shipman Martin
Civil and Environmental Design (Wastewater): Coffey Group
Specialist Drainage Engineering: Capcon Engineering
Interior Fit-Out Specialists: Castle Group Ireland & OCC Construction
Leave a Reply